Exclusive
Nilo Therapeutics Wins Inaugural NewYorkBIO Impact Award Presented by New York City Economic Development Corporation
Overview
Nilo Therapeutics, an early-stage biotech company developing groundbreaking therapies for autoimmune and inflammatory diseases, was selected for its bold innovation, commitment to patient-centered science, and deep roots in the New York community. As the 2025 winner, Nilo received a $15,000 cash prize in recognition of its impact and continued potential to shape the future of health and biotechnology in the city.
The Big Picture
“The launch of the Impact Award marks an important milestone for NewYorkBIO’s mission to highlight and support the incredible innovation advancing New York’s life science community,” said Jennifer Hawks Bland, CEO of NewYorkBIO. “We are proud to give the 2025 award to Nilo Therapeutics as they embody the entrepreneurial and scientific excellence that makes our state’s ecosystem thrive.”
